ATE473739T1 - Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2) - Google Patents

Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2)

Info

Publication number
ATE473739T1
ATE473739T1 AT06753538T AT06753538T ATE473739T1 AT E473739 T1 ATE473739 T1 AT E473739T1 AT 06753538 T AT06753538 T AT 06753538T AT 06753538 T AT06753538 T AT 06753538T AT E473739 T1 ATE473739 T1 AT E473739T1
Authority
AT
Austria
Prior art keywords
aminocarbazole
pge2
prostaglandin
generation
treatment
Prior art date
Application number
AT06753538T
Other languages
German (de)
English (en)
Inventor
Lorenzo Polenzani
Giorgina Mangano
Isabella Coletta
Maria Alisi
Nicola Cazzolla
Guido Furlotti
Caterina Maugeri
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Application granted granted Critical
Publication of ATE473739T1 publication Critical patent/ATE473739T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
AT06753538T 2005-05-19 2006-05-03 Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2) ATE473739T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000909A ITMI20050909A1 (it) 2005-05-19 2005-05-19 Uso di un benzoil derivato dal 3-ammino-carbazolo per la produzione di un farmaco per il trattamento di un disturbo associato alla produzione di prostaglandina e2-pge2-
PCT/EP2006/004348 WO2006122680A1 (en) 2005-05-19 2006-05-03 Use of a benzoyl derivative of 3-aminocarbazole for the treatment of a disorder associated with the production of prostaglandin e2 (pge2)

Publications (1)

Publication Number Publication Date
ATE473739T1 true ATE473739T1 (de) 2010-07-15

Family

ID=35219704

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06753538T ATE473739T1 (de) 2005-05-19 2006-05-03 Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2)

Country Status (23)

Country Link
US (1) US8686021B2 (https=)
EP (1) EP1881826B1 (https=)
JP (1) JP5086991B2 (https=)
KR (1) KR101312579B1 (https=)
CN (1) CN101166528B (https=)
AR (1) AR054126A1 (https=)
AT (1) ATE473739T1 (https=)
AU (1) AU2006246688B2 (https=)
BR (1) BRPI0609718A2 (https=)
CA (1) CA2604562C (https=)
DE (1) DE602006015457D1 (https=)
DK (1) DK1881826T3 (https=)
EA (1) EA012724B1 (https=)
ES (1) ES2347174T3 (https=)
GE (1) GEP20094738B (https=)
IL (1) IL186072A (https=)
IT (1) ITMI20050909A1 (https=)
MX (1) MX2007013491A (https=)
PL (1) PL1881826T3 (https=)
PT (1) PT1881826E (https=)
SI (1) SI1881826T1 (https=)
UA (1) UA94044C2 (https=)
WO (1) WO2006122680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051523A1 (it) 2005-08-03 2007-02-04 Acraf Composto del 3-ammino-carbazolo composizione farmaceutica che lo contiene e metodo per prepararlo
EP2119705A1 (en) 2008-05-14 2009-11-18 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. 3-Aminocarbozole compound, pharmaceutical composition containing it and preparation method therefor
US8792839B2 (en) 2009-05-14 2014-07-29 Qualcomm Incorporated Allocating transmit power among multiple air interfaces

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO2001007409A1 (en) 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
CA2381111A1 (en) * 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
DE10125961A1 (de) * 2001-05-29 2002-12-12 Boehringer Ingelheim Int Carbazolderivate und deren Verwendung zur Herstellung einer Arzneimittelzusammensetzung zur Behandlung von im Zusammenhang mit NPY stehenden Leiden
CA2403307A1 (en) * 2001-10-23 2003-04-23 Neurogen Corporation Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
KR20030042344A (ko) * 2001-11-22 2003-05-28 한국생명공학연구원 에레모필란계 화합물 또는 곰취추출물을 유효성분으로함유하는 염증질환 치료제, 면역질환 치료제, 및 암 치료제
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
KR100402714B1 (ko) * 2002-12-23 2003-11-13 한국생명공학연구원 디테르펜계 화합물을 염증질환, 면역질환 및 암 치료제로사용하는 신규한 용도

Also Published As

Publication number Publication date
EA200702534A1 (ru) 2008-04-28
AU2006246688B2 (en) 2011-09-22
UA94044C2 (ru) 2011-04-11
AU2006246688A1 (en) 2006-11-23
BRPI0609718A2 (pt) 2011-10-18
KR101312579B1 (ko) 2013-09-30
MX2007013491A (es) 2008-01-24
US20080287518A1 (en) 2008-11-20
KR20080018898A (ko) 2008-02-28
EA012724B1 (ru) 2009-12-30
SI1881826T1 (sl) 2010-10-29
CA2604562C (en) 2013-09-17
PL1881826T3 (pl) 2010-12-31
EP1881826B1 (en) 2010-07-14
ITMI20050909A1 (it) 2006-11-20
CN101166528A (zh) 2008-04-23
ES2347174T3 (es) 2010-10-26
DE602006015457D1 (de) 2010-08-26
CN101166528B (zh) 2011-06-15
IL186072A0 (en) 2008-08-07
PT1881826E (pt) 2010-08-05
DK1881826T3 (da) 2010-11-01
CA2604562A1 (en) 2006-11-23
JP5086991B2 (ja) 2012-11-28
IL186072A (en) 2012-05-31
HK1119571A1 (en) 2009-03-13
AR054126A1 (es) 2007-06-06
JP2008540591A (ja) 2008-11-20
GEP20094738B (en) 2009-07-27
WO2006122680A1 (en) 2006-11-23
EP1881826A1 (en) 2008-01-30
US8686021B2 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
EA200801013A1 (ru) Производные замещённых соединений, содержащих конденсированные бензольные кольца, и их применение в качестве лигандов ванилоидных рецепторов
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
ATE475655T1 (de) Verfahren zur herstellung von (s)-4- fluormethyldihydrofuran-2-on
EA200901573A1 (ru) Гетероарилзамещенные тиазолы
ECSP099755A (es) Derivados de pirrolopiridina y su uso como inhibidores de bace
EA201071413A1 (ru) Способ и композиция для лечения повышения внутриглазного давления и глаукомы
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
EA201201178A1 (ru) Пестицидные смеси, включающие изоксазолиновые производные и инсектицид или нематоцидное биологическое средство
EP2171592A4 (en) PARALLELIZATION OF SEQUENCIAL FRAMEWORK CONDITIONS USING TRANSACTIONS
EA201100517A1 (ru) Способ получения дабигатрана и его промежуточные соединения
WO2008156685A3 (en) Tendon stem cells
ATE539054T1 (de) Verfahren zur herstellung von dihydropyrrolderivaten als zwischenprodukte
EA200970871A1 (ru) Новое терапевтическое применение 4-[2-(4-метилфенилсульфанил)фенил]пиперидина
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
EA201100872A1 (ru) Производные хиназолинамида
EA201071120A1 (ru) Способ получения гетероарилбензопроизводных сульфаматов и кристаллической формы n-((2s)-6-хлор-2,3-дигидро-l,4-бензодиоксин-2-ил)метилсульфамида
ATE473735T1 (de) Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
ATE464895T1 (de) Verwendung von benzokondensierten heterocyclischen sulfamid-derivaten zur behandlung von depressionen
EA201170114A1 (ru) Способ получения бензоимидазол-2-илпиримидиновых производных
ATE473739T1 (de) Verwendung eines benzoyl-derivats von 3- aminocarbazol zur behandlung einer erkrankung im zusammenhang mit der erzeugung von prostaglandin e2 (pge2)
DE102006060366B8 (de) Verfahren zur Herstellung von von einer Matrix abgedeckten Quantenpunkten
WO2010028072A3 (en) Avian antibodies specific to influenza virus and technologically simple methods of their manufacture and use
DE50306876D1 (de) Verfahren zur herstellung von alkylarylsulfonaten mittels modifizierter, dimerisierter olefine
ATE520393T1 (de) Verwendung von cb1-rezeptor-antagonisten zur herstellung eines arzneimittels zur behandlung von lebererkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1881826

Country of ref document: EP